ModifiedPremera BluecrossPolicy N/A

Systemic drug therapies for advanced prostate cancer — coverage criteria

Defines medical necessity and coverage criteria for specific oral and intravenous medications used to treat castration-resistant and castration-sensitive prostate cancer, and indicates whether they are managed under the pharmacy or medical benefit. Applies to Premera Bluecross members in North Carolina.

Policy Summary

PayerPremera Bluecross

PolicySystemic drug therapies for advanced prostate cancer — coverage criteria

Policy CodePolicy N/A

Change TypeMaterial clinical update (added Akeega BRCA2 mCSPC indication)

Effective DateN/A

Next Review DateN/A

Key ActionObtain and document BRCA/HRR mutation status and concurrent ADT (or orchiectomy) when requesting authorization for Akeega or other listed agents.

SourceLink

POLICY UPDATE CHANGES

Added Akeega (niraparib and abiraterone acetate) indication for deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC) when used in combination with prednisone.

Added coverage for Akeega for the treatment of deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).

Clarified that medications listed are subject to the product's FDA dosage and administration prescribing information and that non-formulary exception approvals may be issued up to 12 months.

~10drugs specifically addressed

≤12 moauth length (non-formulary)

23%HRR mutation prevalence (mCRPC)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

2026last review year

Coverage Criteria and Indications

Drug-specific medical necessity criteria

Covered when the drug-specific clinical criteria below are met for the indicated disease state and concomitant androgen deprivation therapy (ADT) documentation is provided where required.

Abiraterone products: Abirtega (abiraterone), Zytiga (abiraterone), and Yonsa (abiraterone) may be considered medically necessary for the treatment of individuals with metastatic castration-resistant prostate cancer (CRPC); abiraterone products are covered for metastatic high-risk castration-sensitive prostate cancer (CSPC) when used in combination with ADT.

ADT must be documented by concurrent GnRH analog use or prior bilateral orchiectomy. Yonsa requires coadministration with a corticosteroid (eg, methylprednisolone) and prior inadequate response or intolerance to Abirtega or generic abiraterone.

Combination PARP/androgen pathway agent (Akeega): Akeega (niraparib and abiraterone acetate) may be considered medically necessary for deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC) and for deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC).

Akeega must be used in combination with ADT (documented by GnRH analog or bilateral orchiectomy) and with prednisone.

Androgen receptor inhibitors: Erleada (apalutamide), Nubeqa (darolutamide), and Xtandi (enzalutamide) may be considered medically necessary for indicated disease states including non‑metastatic CRPC (nmCRPC), metastatic castration‑sensitive prostate cancer (mCSPC), and castration‑resistant prostate cancer (CRPC) as specified per agent.

ADT documentation required for combination indications (concurrent GnRH analog or prior bilateral orchiectomy). Specific agent‑level indications vary; refer to agent criteria for HRR‑gene mutation–specific combinations.

Jevtana (cabazitaxel)

Jevtana will be used in combination with prednisone.
The individual has been previously treated with a docetaxel‑containing treatment regimen.

Covered indications and NCCN-aligned systemic therapy coverage

Policy covers systemic therapies for advanced prostate cancer when aligned with NCCN recommendations and specific FDA‑labeled indications for HRR/BRCA‑mutated disease.

Akeega (niraparib + abiraterone) mCRPC indication: Covered for deleterious or suspected deleterious BRCA‑mutated (BRCAm) metastatic castration‑resistant prostate cancer (mCRPC).BRCA gene mutation documented

Added in 2023 Update.

Akeega (niraparib + abiraterone) mCSPC indication: Covered for deleterious or suspected deleterious BRCA2‑mutated (BRCA2m) metastatic castration‑sensitive prostate cancer (mCSPC) when used in combination with prednisone.BRCA2 mutation documented

Added in 2026 Update.

NCCN systemic therapy recommendations for mCRPC: Includes NCCN‑recommended systemic options such as abiraterone, enzalutamide, docetaxel, PARP inhibitors for HRR‑mutated disease (eg, olaparib, talazoparib), Radium‑223 for symptomatic bone metastases, and sipuleucel‑T for select asymptomatic/minimally symptomatic individuals per NCCN guidance.

Historical and referenced coverage indications (summary)

Policy history and reference notes indicating covered indications have been added or updated over time.

Historical additions—early to mid‑2010s: Initial policy established in 2013 with enzalutamide (Xtandi) and subsequent addition of abiraterone (Zytiga) and other agents through 2014–2018 updates, reflecting expanding indications for castration‑resistant disease and combination use with prednisone.

See history entries from 2013–2018.

2021–2024 updates: Policy reviewed prescribing information and NCCN guidelines; Yonsa (abiraterone) criteria added (2018) and later updated to require trial/failure of generic abiraterone (2024). Xtandi and other agents had indication expansions noted in 2023–2024 reviews.

Intermediate updates captured in 2021–2024 history entries.

2023 additions: 2023 Update added coverage for Zytiga and generic abiraterone for BRCAm mCRPC in combination with prednisone and olaparib, added Akeega for BRCAm mCRPC, and expanded HRR‑mutation combinations (eg, Xtandi + Talzenna) per updated FDA labels.

Documented in 2023 Update history.

All uses of medications outside the specific, listed indications and conditions in this policy are considered investigational. The policy states explicitly that "All other uses of the medications listed in this policy are considered investigational." Providers should therefore expect investigational denials when requests are for indications, combinations, or dosing not described in the coverage criteria.

Provenge (sipuleucel‑T) coverage is limited by clinical indication. The policy references NCCN guidance noting that sipuleucel‑T is recommended only for asymptomatic or minimally symptomatic individuals with ECOG 0‑1, and that it is not indicated for individuals with hepatic metastases or with life expectancy <6 months.

This medical policy does not apply to Medicare Advantage. Coverage for services and drugs described here is subject to the limits and conditions of the member's benefit plan and contract; members and providers should consult the member benefit booklet or contact customer service to confirm whether a particular service is covered and any applicable benefit limits.

In the Akeega pivotal analysis, radiographic progression‑free survival (rPFS) improvement in the overall HRR‑mutated population was driven primarily by BRCA2‑mutated patients. An exploratory subgroup of 373 patients with non‑BRCA2 mutations showed an investigator‑assessed rPFS hazard ratio of 0.88 (95% CI: 0.63–1.24), indicating no clear rPFS benefit in that non‑BRCA2 subgroup.

The policy text and history entries in the source do not contain explicit statements labeling any uses of the listed drugs as "not medically necessary." Instead, the document uses the investigational language and documents covered indications, criteria and exclusions; it records additions and clarifications in the history without publishing discrete "not medically necessary" declarations.

Billing and Coding

Medical benefit HCPCS codesHCPCSCovered

J9043

Injection, cabazitaxel (Jevtana), 1 mg

Historical HCPCS code changesHCPCS

A9606	HCPCS code removed from policy
J9043	HCPCS code added historically for Jevtana (cabazitaxel)

Prior Authorization, Documentation, and Operational Notes

Prior Authorization

Benefit management and authorization lengths

- Prior authorization is required for the oral and intravenous agents listed in this policy. Drugs managed through the pharmacy benefit (Abirtega, Akeega, Erleada, Nubeqa, Xtandi, Yonsa, Zytiga and generic abiraterone) are subject to pharmacy benefit prior authorization workflows; drugs managed via the medical benefit (e.g., Jevtana) follow medical benefit authorization processes. - Initial authorizations: non-formulary exception reviews for any drug in this policy may be approved up to 12 months. All other initial pharmacy reviews for oral drugs may be approved up to 3 months; medical benefit initial approvals follow the medical benefit operational rules. - Re-authorization: non-formulary exception reviews and standard reviews for all drugs listed may be approved up to 12 months when drug-specific coverage criteria continue to be met and chart notes document ongoing positive clinical response.

Pharmacy benefit: Abirtega, Akeega, Erleada, Nubeqa, Xtandi, Yonsa, Zytiga, generic abiraterone
Medical benefit: Jevtana (cabazitaxel) - HCPCS J9043

Documentation Required

Non-formulary exception and FDA dosing

Clinical Background

Prostate cancer growth is commonly driven by androgen signaling; disease that progresses despite castrate levels of testosterone is termed castration‑resistant prostate cancer (CRPC). Many therapies covered by this policy act on the androgen axis either by inhibiting androgen biosynthesis (for example, abiraterone) or by antagonizing the androgen receptor (for example, enzalutamide, apalutamide, darolutamide). Some newer combinations target tumor DNA repair defects — for example, PARP inhibitor combinations for tumors with homologous recombination repair (HRR) gene mutations such as BRCA mutations — reflecting the biological dependence of subsets of CRPC on genomic drivers in addition to androgen signaling.

Key Definitions

Castration-resistant prostate cancer (CRPC) definition

DefinitionProstate cancer which has progressed despite local therapy and first-line hormonal therapy assuring castrate levels of testosterone.

ContextTerm commonly used when disease advances despite castrate testosterone — relevant to coverage of systemic therapies for advanced prostate cancer.

Typical patient age distributionApproximately 60% of prostate cancer cases are diagnosed in men 65 years or older; advanced (metastatic) disease has substantially lower 5-year survival.

Androgen deprivation therapy (ADT) documentation requirement

Documentation requirementADT must be documented by concurrent receipt of a gonadotropin-releasing hormone (GnRH) analog or prior bilateral orchiectomy.

When required

Policy Summary

PayerPremera Bluecross

PolicySystemic drug therapies for advanced prostate cancer — coverage criteria

Policy CodePolicy N/A

Change TypeMaterial clinical update (added Akeega BRCA2 mCSPC indication)

Effective DateN/A

Next Review DateN/A

Key ActionObtain and document BRCA/HRR mutation status and concurrent ADT (or orchiectomy) when requesting authorization for Akeega or other listed agents.

SourceLink

On This Page

Meets NCCN indication and performance status requirements

NCCN recommendations referenced for agent selection and sequencing.

Non‑metastatic castration‑resistant prostate cancer (nmCRPC): NCCN‑recommended agents include apalutamide, darolutamide, or enzalutamide, particularly when PSA doubling time <10 months, with consideration of bone protection due to fracture risk.PSA doubling time <10 months or other NCCN criteria

From NCCN guidance.

2026 addition: 2026 Update added a new FDA indication for Akeega for deleterious or suspected deleterious BRCA2‑mutated (BRCA2m) metastatic castration‑sensitive prostate cancer (mCSPC) when used with prednisone.

Marked as a material change in 2026 review.

- All drugs in this policy must be used per the FDA-approved prescribing information for dosing and administration. Requests inconsistent with the product label may be denied unless a non-formulary exception is granted. - Non-formulary exception reviews may be approved for up to 12 months; shorter, time-limited approvals may be applied per operational discretion.

Policy applies FDA dosing and administration prescribing information
Non-formulary exception authorizations: up to 12 months (operationally may be time-limited)

Documentation Required

For oral agents used with androgen deprivation therapy (ADT) — provider documentation required

- For oral agents that require combination with androgen deprivation therapy (ADT) (for example, abiraterone formulations, Akeega, Erleada, Nubeqa, Xtandi, Yonsa, Zytiga and generic abiraterone), documentation must show concurrent ADT by one of the following: gonadotropin‑releasing hormone (GnRH) analog therapy OR prior bilateral orchiectomy. - Approvals for these agents when indicated as combination therapy will require chart documentation of ADT status.

Acceptable ADT documentation: active GnRH analog prescription/administration or documented bilateral orchiectomy
Examples: abiraterone products, Akeega, Erleada, Nubeqa, Xtandi, Yonsa, Zytiga

Prior Authorization

Prescribing information and non-formulary exception

- Prescribers must follow the product-specific FDA prescribing information for indications, dosing, and combination use (e.g., prednisone with certain abiraterone products, olaparib combination indications, or Talzenna combinations). Off‑label or non‑label dosing requires submission of a non‑formulary exception with supporting clinical rationale and documentation. - When a non‑formulary exception is requested, operational limits (including duration of approval) may apply and approvals are granted based on submitted evidence and plan terms.

Follow FDA label for dosing and required concomitant medications (e.g., prednisone with some abiraterone regimens)
Non-formulary exception: require clinical justification and may be time-limited

Step Therapy

Step therapy and combination requirements

- Step therapy and sequencing requirements (for example, trial and inadequate response/intolerance to generic abiraterone before approving certain brand abiraterone products such as Yonsa) are enforced where specified in the drug-specific criteria. - Combination requirements (e.g., required concomitant use with ADT or prednisone, or combination with olaparib or Talzenna for certain HRR/BRCA indications) must be documented to meet coverage criteria.

Example step therapy: Yonsa requires prior trial and inadequate response or intolerance to Abirtega or generic abiraterone
Examples of combination requirements: abiraterone + ADT; Akeega + prednisone + ADT; abiraterone + olaparib per Lynparza label; enzalutamide + Talzenna for select HRR-mutated mCRPC

Required for many oral agents and combinations (e.g., abiraterone products, Akeega) when used in combination with androgen deprivation therapy.

Example from Akeega prescribing notesAkeega should be given concurrently with a GnRH analog or the individual should have had bilateral orchiectomy.

Radiographic progression-free survival (rPFS)

DefinitionRadiographic progression‑free survival (rPFS) is time to investigator‑assessed radiographic progression by bone scan (per PCWG3) or soft tissue lesions by CT/MRI (per RECIST 1.1) or death, whichever occurs first.

Use in trialsrPFS was the major efficacy outcome measure in the Magnitude trial evaluating niraparib plus abiraterone (Akeega) in HRR‑mutated mCRPC.

Interpretation noteExploratory subgroup analyses (e.g., non‑BRCA2 mutations) may show different rPFS effects and inform coverage decisions.

Homologous recombination repair (HRR) gene mutation

DefinitionHomologous recombination repair (HRR) gene mutations are germline or somatic alterations in genes involved in DNA double‑strand break repair (examples: BRCA1, BRCA2, ATM, CHEK2, PALB2, etc.).

PrevalenceHRR gene mutations can be found in approximately 23% of metastatic castration‑resistant prostate cancer (mCRPC).

Relevance to therapyIdentification of HRR mutations (e.g., BRCA2) guides use of PARP inhibitors and combination regimens such as Akeega in HRR‑mutated mCRPC.

Disease state abbreviations (mCRPC / mHSPC / mCSPC)

mCRPCMetastatic castration‑resistant prostate cancer — disease progressing despite castrate testosterone levels; used throughout policy for advanced disease indications.

mHSPCMetastatic hormone‑sensitive prostate cancer — metastatic disease still responsive to initial hormone therapy; addressed in NCCN‑aligned recommendations.

mCSPCMetastatic castration‑sensitive prostate cancer — metastatic disease treated in combination with ADT (policy notes recent Akeega indication for BRCA2‑mutated mCSPC).